Overview

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

Status:
Not yet recruiting
Trial end date:
2026-08-28
Target enrollment:
Participant gender:
Summary
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.
Phase:
Phase 2
Details
Lead Sponsor:
Hansoh BioMedical R&D Company
Treatments:
Tofacitinib